4.8 Review

Pre-eclampsia

期刊

LANCET
卷 398, 期 10297, 页码 341-354

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(20)32335-7

关键词

-

向作者/读者索取更多资源

Pre-eclampsia is a pregnancy disorder characterized by placental malperfusion, leading to hypertension and multi-organ injury, with potential fetal growth restriction and stillbirth. While prophylactic low-dose aspirin can reduce the risk of preterm pre-eclampsia, there are currently no curative treatments once pre-eclampsia is diagnosed except for delivery. Ongoing studies are evaluating various strategies and drugs to prevent and manage pre-eclampsia.
Pre-eclampsia is a multisystem pregnancy disorder characterised by variable degrees of placental malperfusion, with release of soluble factors into the circulation. These factors cause maternal vascular endothelial injury, which leads to hypertension and multi-organ injury. The placental disease can cause fetal growth restriction and stillbirth. Pre-eclampsia is a major cause of maternal and perinatal mortality and morbidity, especially in low-income and middle-income countries. Prophylactic low-dose aspirin can reduce the risk of preterm pre-eclampsia, but once pre-eclampsia has been diagnosed there are no curative treatments except for delivery, and no drugs have been shown to influence disease progression. Timing of delivery is planned to optimise fetal and maternal outcomes. Clinical trials have reported diagnostic and prognostic strategies that could improve fetal and maternal outcomes and have evaluated the optimal timing of birth in women with late preterm pre-eclampsia. Ongoing studies are evaluating the efficacy, dose, and timing of aspirin and calcium to prevent pre-eclampsia and are evaluating other drugs to control hypertension or ameliorate disease progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据